CTVA vs AMGN vs BIIB vs GILD vs REGN

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Corteva, Inc. at 49. 4x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Corteva, Inc. wins at 1. 81x versus Amgen Inc. 's 5. 01x — a reasonable growth-adjusted valuation.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -30. 2% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: CTVA returned +186. 7% versus BIIB's -29. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Regeneron Pharmaceuticals, Inc. 's 0. 81β — meaning REGN is approximately 174% more volatile than CTVA relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 6. 3% for Corteva, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus 15. 1% for CTVA. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Corteva, Inc. (CTVA) is the more undervalued stock at a PEG of 1. 81x versus Amgen Inc. 's 5. 01x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 0x forward P/E versus 21. 6x for Corteva, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 22. 1% to $865. 68.

In this comparison, AMGN (2.

9% yield), GILD (2. 4% yield), CTVA (0. 9% yield), REGN (0. 5% yield) pay a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 9% yield, +186. 7% 10Y return). Both have compounded well over 10 years (CTVA: +186. 7%, REGN: +90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CTVA (Basic Materials) and AMGN (Healthcare) and BIIB (Healthcare) and GILD (Healthcare) and REGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CTVA is a mid-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; REGN is a mid-cap deep-value stock. CTVA, AMGN, GILD pay a dividend while BIIB, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.